Fin Cascade
Get Android appGet iOS app

Prices as of 9 Oct 2026 close · Not investment advice

Dishman Carbogen Amcis Limited

NSE: DCALPharmaceuticals

Share price

₹149.68

+2.06% close of 9 Oct 2026

Market cap ₹2,320 CrP/E 128.9

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

47

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹2,320 Cr

P/E ratio

128.9

P/B ratio

0.4

ROCE

3.1%

ROE

1.6%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹297.6052-week low ₹129.97

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 0.2% over the past year, and 6.1% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 15.3% to 16.6% over the last four years.

Whether it grew faster than its sector

It grew 6.1% a year against a sector median of 13.1% — 6.9 percentage points slower.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

Priced at 0.9 times its growth rate, on earnings growth of 140%.

Profit growthPrice per ₹1 profitPer 1% growth
Dishman Carbogen Amcis Limited — this one140%/yr128.9×—
Torrent Pharmaceuticals22%/yr79.4×₹3.6
Zydus Lifesciences32%/yr23.2×₹0.72
Laurus Labs Limited4%/yr100.5×₹25.1
Cipla10%/yr29.4×₹2.9
Dr Reddy's Laboratories-4%/yr31.2×—

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 110 of 130 on returns, 96 of 127 on growth, 66 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 3.1% on capital, ahead of 15% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Roughly — Over the last five years it made ₹1862 crore of cash from the business and spent about as much on plant and equipment. And the profit is real: of every 100 rupees it reported over 11 years, about 766 arrived as cash — well above the profit; depreciation and interest are the reason, not a windfall. Its cash comes back faster than it used to: it went from being paid 8 days before it paid its own suppliers to paid 60 days before it paid its own suppliers.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

5 of 9 checks clear · 56%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 14 Aug 2026 · Consolidated · Unaudited

Revenue

₹678 Cr

Revenue vs last year

-4.3%

Revenue vs last quarter

-20.4%

Net profit

-₹58 Cr

Profit vs last year

-351.7%

Profit vs last quarter

-363.1%

Net margin

-8.5%

EPS

₹-3.69

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹2,320 Cr
Prev close
₹149.68
52w High
₹303
52w Low
₹129
Enterprise value
₹4,389 Cr
Beta
1.8
Price CAGR 1y
-47.0%
Price CAGR 3y
-1.0%
Price CAGR 5y
-9.0%
Price CAGR 10y
—

Ratios

Return on assets
0.8%
PEG ratio
0.9
P/E ratio
128.9
P/B ratio
0.4
EV / EBITDA
9.0
Industry P/E
37.6
ROCE
3.1%
ROCE 5y average
1.4%
ROE
1.6%
Debt / Equity
0.5
Interest coverage
1.6
Dividend yield
0.0%
ROE 3y average
0.0%
ROE last year
2.0%

Annual P&L

Annual revenue
₹2,932 Cr
Annual profit
₹97 Cr
Operating margin
19.0%
Net profit margin
3.3%
EBITDA margin
19.3%
Sales growth 3y
6.7%
Sales growth 5y
8.9%
Profit growth 3y
140.0%
Profit growth 5y
21.0%
EPS
₹6.2
Sales growth TTM
0.0%
Profit growth TTM
-85.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹678 Cr
Profit latest quarter
-₹58 Cr
YoY quarterly sales growth
-4.3%
YoY quarterly profit growth
-352.2%
OPM latest quarter
8.9%

Balance Sheet

Book Value
₹431
Face Value
₹2.0
Total debt
₹3,076 Cr
Total cash
₹991 Cr
Borrowings
₹3,076 Cr
Reserves / Equity
214.4

Cash Flow

Operating cash flow
₹491 Cr
Free cash flow
₹225 Cr
FCF yield
2.2%
Net cash flow
₹447 Cr

Shareholding

Promoter holding
59.3%
FII holding
6.9%
DII holding
2.1%
Public holding
31.8%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.84,27,3220.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.42,54,5310.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.41,79,3890.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,15,0120.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.41,10,9150.10362.1125.52,026.329.117.8
Cipla1,327.2030.01,07,2210.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.41,03,2610.04574.129.64,030.612.913.5
Dishman Carbogen152.46131.82,3900.00-57.9-327.6677.6-4.33.1
Median417.9034.52,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales723587651655524789682716708653720851678
Expenses602526610592495642542564567504607688618
Material Cost15420634128120145
Change in Inventories-8.24-1080.211415-30
Purchases of Stock-in-Trade000000
Employee Cost325352333356406389
Other Expenses93117137109147114
Operating Profit1226141632914714015314114911316360
OPM %17106.319.575.53192121202316198.87
Other Income7564-448-422871516
Exceptional items (within Other Income)-12-2.6500-1.15-1.69
Interest28273331323749424342464337
Depreciation70758085717272798184848991
Profit before tax29-36-66-49-784227283931-1046-51
Tax %4213-104202183-5639-114245313
Net Profit17-41-60-70-78335432365-1322-58
EPS in Rs1.08-2.61-3.80-4.46-4.952.110.302.751.494.16-0.831.39-3.69
Diluted EPS in Rs2.751.494.16-0.831.39-3.69

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,0311,7141,6952,0592,0441,9122,1412,4132,6162,7122,9322,901
Expenses8301,2611,2491,5071,5401,6381,8092,0812,3292,2432,3662,416
Material Cost593488
Change in Inventories-91-79
Purchases of Stock-in-Trade00
Employee Cost1,2941,447
Other Expenses447511
Operating Profit201452445552503274331332286469566485
OPM %202626272514151411171917
Other Income14264654391629-202245247
Exceptional items (within Other Income)-18-3.80
Interest5649495762485786120159174169
Depreciation69214211240283308308281311294339348
Profit before tax91216231309197-65-4-55-1221910515
Tax %1233333220154-524-4526837
Net Profit80145155210159-16518-30-1533.249716
EPS in Rs9.581310-111.15-1.90-9.790.216.221.03
Diluted EPS in Rs0.216.22
Dividend Payout %00020000000

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
11%
5 years
9%
3 years
7%
TTM
0%

Compounded profit growth

10 years
—
5 years
21%
3 years
140%
TTM
-85%

Stock price CAGR

10 years
—
5 years
-9%
3 years
-1%
1 year
-47%

Return on equity

10 years
1%
5 years
0%
3 years
0%
Last year
2%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital160323231313131313131
Reserves8634,8145,0755,3475,6845,6675,5185,7785,5965,8006,646
Borrowings8689501,0951,0421,3571,5891,8302,2092,3132,3893,076
Other Liabilities3348119678991,1211,0681,2551,4211,6311,7662,158
Minority Interest00
Total Liabilities2,0816,5747,1697,3218,1938,3568,6349,4399,5719,98711,911
Fixed Assets1,0124,8525,0665,0985,6785,6985,7736,1886,7247,0558,076
CWIP3071331511752344867801,043646467570
Investments1401961671911723242491029791
Other Assets7611,5501,7571,8812,0912,0001,7581,9592,0982,3683,174
Total Assets2,0816,5747,1697,3218,1938,3568,6349,4399,5819,99911,911

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity203303226282585513355266379371491
Cash from Investing Activity-231-107-297-169-442-380-619-494-225-192-245
Cash from Financing Activity25-13778-102-98-11130250-22-102201
Net Cash Flow-35971146122-1332213277447
Free Cash Flow-3716422-26177147-101-35276156225

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days60619679103808189689084
Inventory Days272473525496462402526568540655910
Days Payable17295201176226132158155149168189
Cash Conversion Cycle160439419399340350449502458577805
Working Capital Days-52354443-10-2-8-37-148-35-60
ROCE %564011023

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters595959595959595959595959
FIIs8.808.608.708.058.188.759.499.948.077.667.456.86
DIIs3.513.682.361.471.221.421.261.271.371.271.632.06
Public282830313131302931323232
No. of Shareholders56,27252,33650,65653,68355,28052,82250,75749,74449,45548,48149,00949,430

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -47.2% (₹283.50 → ₹149.68)Brick size ₹6.27 (fixed)Bricks 74
₹200₹250₹300₹150Nov '25Jan '26Mar '26May '26Jul '26Sep '26
Price moved up one brickPrice moved down one brickLast close ₹149.68 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

2,069inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

24,79,229inr

2026-03-31

News

News and filings about Dishman Carbogen Amcis Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • API starting materials, intermediates and fine chemicals
  • Specialty chemicals and phase-transfer-catalyst feedstocks
  • Wool grease / lanolin

Sells to

  • Boston University School of Medicine · 25-hydroxyvitamin D3 capsules

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE385W01011

Plants

  • Carbogen Amcis Aarau
  • Carbogen Amcis Bubendorf
  • Carbogen Amcis Hunzenschwil
  • Carbogen Amcis Manchester
  • Carbogen Amcis Riom
  • Carbogen Amcis Veenendaal
  • Carbogen Amcis Vionnaz
  • Dishman Bavla API Plant
  • Dishman Carbogen Amcis Shanghai
  • Dishman Naroda Plant

News impact

Big market events that reach Dishman Carbogen Amcis Limited, and how the effect spreads.

Who it hits first

  • Launch-heavy drug makers (Sun, Cipla) gain months of extra sales per approval.
  • API suppliers and CDMOs see more client molecules to make.
  • Hospitals unaffected — approvals do not fill beds.

Who may gain

  • Sun Pharma most in absolute terms; quality API makers (Gujarat Themis) on volumes.

Along the supply chain

Downstream

Distributors and pharmacies stock more new products; hospitals mostly unaffected.

Upstream

API and intermediate makers gain volumes as more launches need ingredients.

Where demand moves

Business

Approval queues shorten; API/CDMO order books lengthen; patients access drugs sooner.

Capital

Money rotates into launch-heavy pharma and quality API names; avoids weak-balance-sheet theme traps.

How it spreads across sectors

Healthcare

Pharma and CDMO positive with a lag; hospitals neutral; weak names are value traps.

When it plays out

Immediate

Pharma stocks firm 1-3% on sentiment; weak names jump most (sell the jump).

Medium term

Actual approval acceleration over 1-3 years compounds launch-heavy winners.

Short term

Draft details and implementation dates decide how much is real vs hope.

Who it hits first

  • Piramal Pharma faces CDMO order pauses, deeper client audits and remediation costs at Morpeth.
  • Seven observations exceed its own 4-observation precedents, signaling a tougher inspection outcome.
  • Small pharma peers derate on sentiment as investors re-check Indian plant quality systems.

Who may gain

  • Large quality leaders (Sun, Divi) may pick up marginal CDMO inquiries — too small to trade.

Along the supply chain

Downstream

US clients of Morpeth qualify backup suppliers slowly; no drug shortages indicated.

Upstream

No direct supply-chain link — this is a plant-quality event, not a supply disruption; API suppliers to Morpeth see minor order delays.

Where demand moves

Business

CDMO clients slow new Piramal orders and audit harder; no demand transfers at scale to peers.

Capital

Money trims small-pharma exposure on regulatory headlines; rotates to large quality pharma and hospitals-on-facts.

How it spreads across sectors

Healthcare

CDMO/API sentiment hit; hospitals untouched operationally; large pharma flat per precedent.

When it plays out

Immediate

Piramal stock down 2-5% on the headline; small peers dip 1-3% on sentiment.

Medium term

Clean re-inspection closes the episode; warning letter or import alert would extend damage to quarters.

Short term

Company corrective-action response and FDA classification (VAI vs OAI) decide whether this fades or escalates.

Who it hits first

  • Granules faces 2-4% technical pressure from Rs 1,500 cr of new free float
  • Quality buyers (Goldman, BNP) validate the business and likely mark a near-term floor
  • Pharma peers see no fundamental change — ranked names are sentiment-only

Who may gain

  • Goldman Sachs, BNP Paribas and other block buyers who accumulated at a discount
  • Granules' public float and liquidity improve post-deal

Along the supply chain

Downstream

Formulation customers and distributors are unaffected; pricing and contracts continue as before.

Upstream

No supply-chain link — API suppliers and job-workers see no order change from a share sale.

Where demand moves

Business

No business demand shifts — this is a pure ownership transfer; Granules' API and formulations orders are untouched.

Capital

Promoter supply meets institutional demand at a small discount; some weak holders exit on the news while quality funds accumulate — net neutral to mildly positive for the register.

How it spreads across sectors

Healthcare

neutral — single-stock block with quality buyers; no sector read-through

When it plays out

Immediate

Granules dips 2-4% on supply overhang; peers flat

Medium term

Non-event for earnings — price rejoins fundamentals within a quarter

Short term

Block gets absorbed in 1-2 weeks; quality-holder register supports stability

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

12 Sep 2019unspecified₹0.2

Splits, bonuses & buybacks

  • daily-prices repair: 8 rows from NSE's archive (replace 1, delete 1, insert 6), 2020-02-01..2026-02-01 (docs/flat_day_repair.md)1× · 1 Feb 2020

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.